Tag Archives: TEVA

Tuesday’s Midday Stock Update: Rite Aid (RAD), Teva Pharmaceutical Industries (TEVA), Bluebird Bio (BLUE), Blueprint Medicines (BPMC), SunPower (SPWR)

So far Tuesday, January 14, NASDAQ is up 0.1% and the S&P is up 0.51%. Here are this morning’s most active stocks: Rite Aid (RAD – Research Report), Teva Pharmaceutical Industries (TEVA – Research Report), Bluebird Bio (BLUE – Research

Thursday’s Highlights at Noon: Clovis Oncology (CLVS), Intercept Pharma (ICPT), Veeva Systems (VEEV), Bluebird Bio (BLUE), Teva Pharmaceutical Industries (TEVA)

So far Thursday, November 28, NASDAQ is up 0.23% and the S&P is up 0.87%. Here are this morning’s most active stocks: Clovis Oncology (CLVS – Research Report), Intercept Pharma (ICPT – Research Report), Veeva Systems (VEEV – Research Report),

Sunday’s Highlights at Noon: Teva Pharmaceutical Industries (TEVA), UnitedHealth (UNH), Ebix (EBIX), Omeros (OMER), Cormedix (CRMD)

So far Sunday, November 17, NASDAQ is up 0.17% and the S&P is up 0.77%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Teva Pharmaceutical Industries (TEVA – Research Report), UnitedHealth (UNH –

Friday’s Midday Movers: Ebix (EBIX), Teva Pharmaceutical Industries (TEVA), Aerie Pharma (AERI)

So far Friday, November 15, NASDAQ is up 0.09% and the S&P is up 0.34%. Here are this morning’s most active stocks: Ebix (EBIX – Research Report), Teva Pharmaceutical Industries (TEVA – Research Report) and Aerie Pharma (AERI – Research

Saturday’s Midday Stock Update: Teva Pharmaceutical Industries (TEVA), Recro Pharma (REPH), Glu Mobile (GLUU), Sangamo Biosciences (SGMO), Sarepta Therapeutics (SRPT)

So far Saturday, November 9, NASDAQ is up 1.9% and the S&P is up 1.14%. Here are this morning’s most active stocks: Teva Pharmaceutical Industries (TEVA – Research Report), Recro Pharma (REPH – Research Report), Glu Mobile (GLUU – Research

RBC Capital Maintains Their Hold Rating on Teva Pharmaceutical Industries Limited (TEVA)

RBC Capital analyst Randall Stanicky maintained a Hold rating on Teva Pharmaceutical Industries Limited (TEVA – Research Report) yesterday and set a price target of $10. The company’s shares opened today at $7.09, close to its 52-week low of $6.34.